Performing with a smooth maneuver as a bailout in cases of coronary ostia impairment or severe prosthetic leak due to higher deployment for a suboptimal sealing of the device, valve calcification or local or accidental embolization occurred during early experience with the new ACCUTRACK delivery system. In a 6 mm 2nd CRS in the correct position was implanted. The misplaced CRS functioned normally, with no instances of structural deterioration, thrombosis or further distal migration, and showed complete apposition against the aortic wall. Moreover, no thromboembolic events were reported in any patient.

Conclusion: CRS embolization can be effectively managed, implanting a second prosthesis in a standard fashion and leaving the misplaced device in aorta. There seem to be no long-term vascular or local and neurological adverse events associated with device embolization or intentional relocation in experienced hands.

TCT-769

Requirement of Small Size of Prosthetic Aortic Valve in Asian Population: Implication to Select Valve Size for Transcatheter Aortic Valve Implantation in Elderly

Mai Saji1, Morimasa Takayama1, Tetsuya Tobu1, Minora Tabata1, Jun Nakata1, Hiroyuki Watanabe1, Shiuchiro Takenashi2, Tetsuya Sumiyoshi1, Hitonobu Tomoke1
1Cardiology, Sakakibara Heart Institute, Tokyo, Japan; 2Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo, Japan

Background: Currently an efficacy of transcatheter aortic valve implantation (TAVI) has been proved as a less invasive treatment for high risk elderly patients with aortic stenosis in Europe and United States, and many patients received TAVI. However, there is no data regarding to appropriate size of aortic valve by TAVI in Asian population who has smaller build than those in Europe and United States. To clarify aortic annular size in Japanese patients with aortic stenosis, the following study was evaluated.

Methods: Between May 2004 and December 2008, consecutive 340 patients (male: 158, female: 182) who underwent surgical replacement of aortic valve for aortic stenosis were studied. Study subjects included tricuspid anatomy in 224 patients and bicuspid in 116 patients. Because of indication for TAVI, patients with tricuspid anatomy were evaluated by TTE (transesophageal echocardiography) and TEE (transesophageal echocardiography). We analyzed the sizes of annulus and implanted valve.

Results: Patient age was 72.9±8.4 years old (male) and 75.8±6.6 years old (female). Annulus diameter was 21.1±2.1 mm (male 22.3±1.9 mm, female 20.3±1.9 mm, p<0.001). The average annulus diameter above 75 years old also had larger size in male than female (n=42, 22.3±2.0 mm vs.22.0±1.8 mm). Implanted valve was smaller than measured annulus both in male (21.1±1.4 mm) and female (19.3±1.3 mm). Small size valve bellow 20 mm was counted in 31.5% of whole patients, and 46.3% of female patients above 75 years old. Conclusion: Asian population including Japanese shall need a smaller size of prosthetic aortic valve in elderly. Furthermore, considering the thickness of sewing ring of tissue valve, Euro-American population may also require a small size valve in case of value-in-use technique.

TCT-770

FRANCE II: French registry aortic corevalve and Edwards registry II

Martine Gilard1, Marc Laskar2, Patrick Donouze Gouge3, Karine Chevreuil4, Helene Elchannoff4, Jean Faucat4, Pascale Leprince4, Alain Leguerrier4, Alain Prat4, Emmanuel Teiger5
1Brest University, Brest, France; 2CHU Limoges, Limoges, France; 3Institut Jacques Cartier, Massy, France; 4Le Pitié Salpêtrière, Paris, France; 5CHU Rouen, Rouen, France

Background: Transcatheter aortic valve implantation is a therapeutic alternative for high-surgical-risk patients with severe symptomatic aortic stenosis. Two models of prostheses are currently commercialized in France, which can be implanted either via a transapical or a transapical approach. The aim of the study was to evaluate in a national French registry the early safety and efficacy of transcatheter aortic valve replacement (AVR) using either the Edwards valves or CoreValve in high-surgical-risk patients with severe aortic stenosis.

Methods: The multicentre national registry was conducted in 33 centres between January 6th 2008 and July 11th, under the authority of the French Society of Cardiology and Thoracic and Cardio-Vascular Surgery. All the valves implanted in France since the study period were included. The primary endpoint was mortality at 1 month, 6 month, 1 year up to 5 year.

Results: Two thousand and five hundred high-surgical-risk patients (logistic EuroSCORE ≥20%, STS ≥10%, or contra-indication to AVR) were enrolled. Mean age was 82±7 years and 43.9% were female. Edwards valves and CoreValve were implanted in 68 and 32% of patients, respectively. The approaches used were transapical (transapical: 66%; subclavian: 5%) or transapical in 29%. Device success rate was xx and mortality was xx, xx, xx respectively at 30 days, 6 month and 12 month. Severe complications included stroke (xx), tamponade (xx), acute coronary occlusion (xx), and vascular complications (xx). Atriumet was required in xx. At 1 month, xx of patients were in NYHA class II or less, xx at 6 month and xx at 1 year. All these result will be presented at ESC and end of August 2011.

Conclusion: This prospective registry reflects the real-life experience of transcatheter aortic valve implantation in high-risk elderly patients in France. This registry is the first exhaustive and consecutive registry included the 2 types of percutaneous aortic valves.

TCT-771

Expanded Anatomic Suitability of Current Generation Transcatheter Aortic Balloon-Expandable Prostheses

Massimo Napoli1, Ermel2 Yezirli, Valeria Gasparetto3, Chiara Fraccaro1, Giuseppe Tarantini, Paolo Basso, Augusto D Onofrio, Demetrio Pittarello, Gino Gerossa, Giambattista Isabella, Sabino Illiceto
1Dpt. of Cardiac Thoracic and Vascular Sciences. University of Padova, Padova, Italy

Background: The percentage of patients eligible for first-generation balloon-expandable Edwards SAPIEN valve (Edwards Lifiences, Irvine, California, USA) implantation was restricted to definite aortic annulus diameters. Moreover, transfemoral implantation using this device was limited to patients with large bore iliac-femoral arteries. This study sought to assess the proportion of patients anatomically suitable for the current Edwards SAPIEN XT (ES-XT) valve using Novalflex/E-Sheath delivery system compared with the past Edwards SAPIEN (ES) valve with Retroflex 3 delivery system, including both transfemoral and transapical approaches.

Methods: All high surgical risk patients with severe aortic stenosis referred to our department as potential candidates for TAVI, underwent transesophageal echocardiography and angiography of aorta and iliac-femoral arteries in order to assess anatomical suitability by different approaches. The transfemoral access requirements for ES/Retroflex 3 system were a minimal iliofemoral lumen diameter of at least 7 mm for the 22-F/23-mm device and a minimal iliofemoral dimension of at least 8 mm for the 24-F/26-mm device. The current ES-XT with Novalflex/E-Sheath delivery system requires a minimal iliofemoral dimension of at least 6 mm for the 23 mm valve (Novalflex 18F/E-Sheath 16F) and 6.5 mm for the 26 mm valve (Novalflex 19F/ E-Sheath 18F). The range of annulus diameter considered amenable for implantation was 18.5 mm for the ES valve (23 and 26 mm prosthesis) and 18.75 mm for ES-XT valve (23, 26 and 29 mm prosthesis). Transapical approach was considered as the first option, if not suitable the patient was evaluated for transapical approach.

Results: Data were collected for 293 high-risk patients evaluated for TAVI. Anatomical suitability was 82% (240/293) for ES Retroflex versus 69% (277/293) for ES-XT E/Sapien/E-Sheath. Among 240 patients eligible for ES Retroflex, 80 (33%) were suitable for transfemoral implantation, while among 277 patients eligible for ES-XT, those suitable for tranfemoral approach were 172 (62%).

Conclusion: Using current Edwards devices the percentage of patients suitable for TAVI increases from 82% to 95%. Moreover, while only 1/3 of patients had anatomic criteria suitable for the less-invasive transfemoral approach with the previous devices, with the current Edwards SAPIEN devices this proportion increases to about 2/3 of patients.
TCT-773
Prediction of Optimal Deployment Projections in Transcatheter Aortic Valve Replacement: Angiographic 3-Dimensional Reconstruction of the Aortic Root versus Multidetector Computed Tomography
Ronald Karl Binder1, Jonathon Leipisch2, David A Wood3, Teri Moore2, Stefan Togweiler4, Alex Willson5, Ronen Garvitch6, John G Webb7
1St. Paul’s Hospital - University of British Columbia, Vancouver, Canada; 2Siemens Healthcare, Research Collaborations, San Francisco, CA

Background: Identifying the optimal fluoroscopic valve projection is important for successful transcatheter aortic valve replacement (TAVR). We compared angle predictions from 3-dimensional angiographic reconstructions (3DA) of the aortic root to those from multidetector computed tomography (MDCT).

Methods: Patients undergoing transfemoral TAVR underwent pre-implant 3DA and baseline MDCT. Two separate independent operators predicted percutaneous valve projections for each method prospectively. The angles generated from 3DA and MDCT as well as the final implant angle were compared to the post deployment percutaneous valve projection. 3DA reconstructions were generated from a 220 degree rotational aortic root angiogram during breath hold and rapid ventricular pacing. The shortest distance from the post deployment percutaneous valve projection to the regression line of predicted percutaneous valve views were calculated for every patient and method.

Results: 39 out of 40 patients had adequate image quality for reproducible angle predictions. There was a significant correlation between 3DA and MDCT for predictions of percutaneous valve projections (r = 0.682, p<0.001, figure 1). Deviation from the regression line of predicted angles to the post deployment valve view were 5.1±4.6° for 3DA and 7.9±4.9° for MDCT (p = 0.016). The mean deviation from the implant angle to the post deployment perpendicular valve view was 1.9±4.6° RAO/LAO and 5.1±7.2° cranial/caudal.

Conclusion: Both 3DA and MDCT are accurate and safe imaging modalities for identifying the optimal valve deployment projection in TAVR.

TCT-774
Feasibility And Safety Of Transaortic Transcatheter Aortic Valve Implantation In Patients With Previous Cardiac Surgery Using the Edwards SAPIEN Bioprosthesis
Muhammad Zeeshan Khwaja1,2, Rizwan Attia1, Andres Diaz1, Ahsok Naryanan3, Jane Hancock4, Simon Redwood5, Martyn Thomas6, Vinayak Bapat7
1Cardiology, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom; 2The Rayne Institute, King’s College, London, United Kingdom;
3Department of Anaesthetics and Intensive Care Medicine, Essen, Germany; 4West German Heart Center Essen University Hospital, University Duisburg-Essen, Department of Cardiology, Essen, Germany; 5West German Heart Center Essen, University Duisburg-Essen, Department of Cardiothoracic and Vascular Surgery, Essen, Germany; 6West German Heart Center Essen, University Duisburg-Essen, Department of Anaesthesiology and Intensive Care Medicine, Essen, Germany

Background: Patients with severe aortic stenosis (AS) and a history of previous cardiac surgery who require valvular intervention have an increased peri-operative risk.

Transcatheter aortic valve implantation (TAVI) is increasingly popular in such high-risk patients. If peripheral vascular disease precludes transfemoral implantation (TF-TAVI), the transapical approach (TA-TAVI) is used. However this is associated with pleural disruption and compromise of the left ventricular (LV) continuity. We sought to evaluate the feasibility of the retrograde, transaortic technique (Tao-TAVI) using the Edwards SAPIEN valve as an alternative approach avoiding these problems. Methods: 196 patients with severe aortic stenosis underwent TAVI at St Thomas’ Hospital, London, between January 2008 and March 2011. 59 patients had previously undergone cardiac surgery and of these 7 patients underwent Tao-TAVI after considerations of anatomy, risk, LV function and significant respiratory disease. 6 had previous coronary artery bypass grafting (85.7%) and 1 patient (14.3%) had 2 previous cardiac operations for resection of subaortic membrane and ventricular septal defect closure. All patients had CABG and had grafts including LIMA to LAD and saphenous vein grafts to native coronaries.

Results: In the Tao-TAVI group the mean age (mean±SD) was 75.1±13.5 years. 71.4% were male. Mean logisitic EuroScore was 30.4±20.1. Pre-TAVI peak transaortic gradient was 84.6±34.4mmHg and fell to 13.6±5.7mmHg immediately post-procedure (p=0.002).

Conclusion: TAO-TAVI is a feasible option in high-risk redo patients with patent coronary grafts and may provide a preferable access route in these high-risk patients when TF-TAVI is not possible, avoiding the LV and respiratory complications of TA-TAVI.

TCT-775
Improved Procedural Results After CoreValve Implantation with the New AccuTrak Delivery System
Emmanuel Chorianopolous1, Ulrike Krumsdorf2, Sven T Pleger2, Hugo A Katus2, Rafii Bekeredjian2
1Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, Heidelberg, Germany
2Cardiovascular Institute, University of California, San Francisco, CA

Background: Transcatheter aortic valve implantation (TAVI) has become an established treatment for severe aortic stenosis in patients with unacceptable high surgical risk. Recently, the new AccuTrak delivery system for improved deliverability of the CoreValve aortic bioprosthesis was launched. It has not been shown yet, if the new delivery catheter leads to optimized positioning and improved procedural outcomes.

Methods: We therefore conducted a retrospective single-center analysis comparing the procedural results after transfemoral CoreValve implantation with or without the new AccuTrak delivery system.

Results: We evaluated 70 consecutive patients (35 with the original delivery catheter and 35 with the new AccuTrak catheter) for procedural results after CoreValve implantation. The use of the AccuTrak delivery catheter resulted in significantly higher positioning of the CoreValve prosthesis (8.8 mm [7.1 to 11.2 mm] vs. 7.0 mm [5.5 to 9.4 mm]; P=0.0068) below the annulus (median [interquartile range]). Moreover, the optimized positioning resulted in reduced rates of significant (≥ grade 2) aortic regurgitation assessed by postinterventional aortography and echocardiography (P=0.044 and P=0.0275 respectively). Despite improved positioning, no differences in the need for permanent pacemaker implantation were observed.

Conclusion: Our retrospective analysis demonstrates improved positioning and reduced postinterventional aortic regurgitation with the new CoreValve AccuTrak delivery system. Whether this may also affect the need for permanent pacemaker insertion or long-term outcome after TAVI needs to be evaluated in larger studies.

TCT-776
Outcome of Residual Paravalvular Aortic Regurgitation (PAR) After Transfemoral Aortic Valve Implantation (TAVI) And Importance of Hemodynamic Assessment
P C Pillatsch1, Thomas FM Konorza2, Fadi Al-Rashdi3, Björn Plicht1, Daniel Westermark1, Matthias Thielemann1, Lars Bergmann1, Heinz Jakob3, Holger Egggebrecht2, Raimund Erbel2, Philipp Kahler1
1West German Heart Center Essen University Hospital, University Duisburg-Essen, Department of Cardiology, Essen, Germany; 2West German Heart Center Essen, Essen University Hospital, University Duisburg-Essen, Department of Cardiothoracic and Vascular Surgery, Essen, Germany; 3West German Heart Center Essen, Essen University Hospital, University Duisburg-Essen, Department of Anaesthesiology and Intensive Care Medicine, Essen, Germany

Background: Residual PAR after TAVI is common. However, systematic data on its severity and its clinical impact are sparse. We, therefore, thought to evaluate incidence, severity and outcome of residual PAR after TAVI.

Methods: We analyzed data from 167 consecutive TAVI patients treated with either the Medtronic-CoreValve (n=88) or the Edwards Sapien (n=79) bioprosthesis. PAR was graded angiographically according to the Sellers criteria at the end of the procedure. In addition, invasive hemodynamics post implantation/pressure difference: diastolic aortic pressure – LVEDP (PD DAP–LVEDP)) were analyzed.

Results: TAVI was technically successful in all patients with overall mortality rates of...